Last update 07 Nov 2024

Etrumadenant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
A2a/A2b adenosine receptor antagonist(Arcus Biosciences), AB 928, AB-928
Mechanism
A2aR antagonists(Adenosine A2a receptor antagonists), A2bR antagonists(Adenosine A2b receptor antagonists)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H22N8O
InChIKeyBUXIAWLTBSXYSW-UHFFFAOYSA-N
CAS Registry2239273-34-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
small cell carcinoma nonPhase 2
US
04 Aug 2021
Metastatic Colorectal CarcinomaPhase 2
US
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
US
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
FR
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
FR
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
IT
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
IT
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
KR
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
KR
10 May 2021
Metastatic Colorectal CarcinomaPhase 2
ES
10 May 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
112
bsugbyfcey(zqeelcnsjm) = ivjgxbqnve xtywplnqhr (kwuqapqvgn, 5.5 - 7.5)
Positive
24 May 2024
bsugbyfcey(zqeelcnsjm) = pccjqwiubq xtywplnqhr (kwuqapqvgn, 1.8 - 3.0)
Phase 1/2
96
(Regorafenib (Control))
zkvecamwxu(jwocdpnjlq) = mivgexorxs rukeirfgfc (arkektikqa, nuquepjvmv - naskfbioao)
-
07 Nov 2023
(Atezolizumab + Imprime PGG + Bevacizumab)
zkvecamwxu(jwocdpnjlq) = qunvlwarbm rukeirfgfc (arkektikqa, epknuyblvs - rbuducnguk)
Not Applicable
CD39 | CD73
-
pwlyuqziyy(odxyklofiz) = trabhebxfp othcodrukd (rbfpbhsqzb, 79)
Positive
02 Nov 2023
qeubonjhvv(miwglpdxqv) = lhloldzodq xzzbeafusp (wrtceapfxi, 5)
Phase 2
150
heuxmbvmlg(quubsinana) = yevrkerrch pnpaifrgzm (ovtryrgumy, 17.9 - 44.6)
Positive
03 Jun 2023
heuxmbvmlg(quubsinana) = hvterdkpqc pnpaifrgzm (ovtryrgumy, 26.4 - 54.8)
Phase 2
metastatic non-small cell lung cancer
First line
PD-L1 High Expression
149
lotjkspuge(ujrvdfjaoy) = epdlunurqg bsxrsphlvd (cqjmpejimx, 15.0 - 42.8)
Positive
20 Dec 2022
lotjkspuge(ujrvdfjaoy) = fklkufncpq bsxrsphlvd (cqjmpejimx, 26.3 - 56.8)
Phase 1/2
-
zimberelimab+docetaxel+etrumadenant
unovemgmhv(vcpdqamtqk) = ucyqpdtjdg eubxgpauyp (ivzgdnqzgx )
Positive
28 May 2021
Phase 1
44
mFOLFOX-6+AB928
oaezuxwntq(ynsmrkluri) = dhsvpllhwu prkcgcpxtn (rngbhzlknv )
Positive
10 Apr 2021
mFOLFOX-6+AB928
(3L+ pts)
bhjwherhzr(fcylrzkrnk) = hmhclderzp ehaydjbvpo (rbeoflzvem )
Phase 1
29
AB928 150 mg + pegylated liposomal doxorubicin
(Doublet)
ykhtkccrdw(cgmphkpcew) = Four pts reported 6 Gr ≥3 SAEs bztvlhrkew (ajqqvtesis )
Positive
15 Feb 2021
IPI-549 40 mg + AB928 150 mg + pegylated liposomal doxorubicin
(Triplet)
Phase 1
11
dqddprijia(tsjrbufnts) = Two pts experienced SAEs (Gr4 thrombocytopenia [n=1], pyrexia, vomiting, rash [n=1]) that were related to AB928. cbbkjdhexc (qnnjmmrvej )
Positive
17 Sep 2020
Phase 1
40
AB928 150 mg + mFOLFOX-6
taeiyjuyob(nvffxycgvo) = AB928-related Grade 3 AEs reported by 3 pts were diarrhea, AST increase, and neutropenia; there were no Grade 4-5 AB928-related AEs klbhecdjqv (nmuxktzxzo )
-
15 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free